In this workflow, we will provide an overview of how Synapse can assist in conducting competitive evaluations using our Competitive Landscape feature. This feature empowers you to analyze a wealth of information for a given drug type effortlessly, enabling well-informed decisions such as whether to enter a specific space. The workflow's beauty lies in Synapse's ability to gather multiple key datasets in one place, ensuring that you and your team do not overlook any critical information when making business decisions.
Once you are on the homepage of Synapse, you will see an option to expand the sidebar on the top left of the screen.
Once you have done that, you will see that the platform offers a variety of search options to cater to diverse needs. We will be utilizing the "Competitive Landscape" option. Once you are on the Competitive Landscape search screen, you'll notice that we can actually look at targets, indications, and drug types:
Additionally, you'll notice the presence of pre-populated interactive charts that you can utilize. For example, the chart in the image above showcases the top targets in each R&D status, focusing on phase two drugs and the top 10 targets. Now, let's zoom in on a specific drug type. Navigate to the "Drug Type" tab and search for "Monoclonal antibody" as an example. You'll notice that when you start typing, the system conveniently displays the desired drug type which you can simply click on. This is due to the Smart Search functionality. Clicking on "Monoclonal antibody" will open up a detailed page dedicated to the selected drug type, similar to the page you might have observed on the company detail page. On this page, we will find a wealth of information allowing you to assess the specific drug type and gain insights into its landscape.
You will see at the top of the page that we have an overview table that provides general information on Monoclonal antibodies. For example, there are 5,915 drugs in total associated with monoclonal antibodies, with 51 drugs added in the last 30 days. Additionally, there are over 1,000 indications and targets associated with this drug type as well as over 34,000 clinical trials. The table is interactive in case you were looking to further assess the Clinical Trial or Drug information.
If you scroll down, you will see a number of heatmaps that provide more insights into the drug type. The "Organizations Heatmap" offers an overview of the top 100 organizations and the drugs they currently have in this space. As you continue scrolling, you will find the "Target Heatmap" and "Disease Heatmap", offering further insights into the landscape.
To emphasize the interactivity of Synapse, let's revisit the "Organizations Heatmap." Imagine you're interested in Roche, a major player in this drug type. By simply clicking on the number next to Roche's name, you can easily view the drugs approved for this specific drug type by company. By clicking on the number 20, it will take you to a search output showcasing those 20 drugs.
This functionality is applicable to other heat maps as well. For instance, if you are interested in drugs associated with the target TNF-alpha, you can click on the number 38 under the "Approved" column, which will provide a similar search output but with different drugs.
From there, you can further refine your search by adding criteria such as drugs approved only in the United States, allowing you to make granular searches. Additionally, you can also set up email alerts to notify you of any changes related to your specific search.
In conclusion, by leveraging the competitive landscape feature, you can effortlessly analyze vast amounts of information on drug types, enabling you to make well-informed decisions. Synapse's consolidation of key datasets, intuitive search options, interactive graphs, and detailed pages work together to provide you with valuable insights. Whether you are exploring drug approvals, studying market trends, or evaluating specific organizations, Synapse empowers you with the tools necessary to navigate the complex landscape of the pharmaceutical industry effectively.
Comments
0 comments
Please sign in to leave a comment.